The 20 biggest venture raises year-to-date: genetic medicines dominate
Among biotechs that have raised venture rounds of over $100M this year, nearly half are developing genetic medicines
ElevateBio’s $401 million series D round, announced Wednesday, and ReNAgade’s $300 million A round the day before mark two of the three largest biotech venture financings so far this year. Both companies are developing genetic medicine platforms.
As of Thursday, 20 companies had disclosed raising venture rounds of over $100 million, according to BioCentury’s BCIQ database. Eight (40%) of these companies are developing nucleic acid or cell-based therapies, or the tools to create such therapies. ...